1. Scrip

Serum Scores A Double - HPV Vaccine In India, Novavax Vaccine In US

Demand High For HPV, Low For COVID-19 Vaccine

 
• By Vibha Ravi

Serum Institute will supply initial doses of NVX-CoV2373 in the US, but late approvals have meant Novavax's vaccine is facing weak demand and surplus stocks in other parts of the world. Meanwhile, Serum has also secured a nod in India for the first indigenously-developed HPV vaccine, also the fifth globally.

Victory
Serum Institute Will Benefit From Twin Approvals • Source: Shutterstock

Sometimes timing is everything. Novavax, Inc. would be realizing that, given its COVID-19 vaccine has only recently secured an emergency use authorization (EUA) in the US, despite having an early start to its development program for NVX-CoV2373.

While mRNA rivals Pfizer Inc./BioNTech SE and Moderna, Inc. whizzed past in 2020, Novavax faced manufacturing troubles and a non-fast-tracked review of the vaccine’s data. Now, experts doubt much demand remains for primary immunization in the US, for which the vaccine is approved

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip